Among the 3 PD-L1 isoforms (isoform a, isoform b, and isoform c), isoform b inhibits T cells more effectively than isoforms a and c in colorectal cancer, suggesting that isoform b is a potential target for immunotherapy.129 These studies suggest that different PD-L1 isoforms are generated by alternative splicing and may play important roles in oncotherapy. Here, CD274 is linked to colorectal cancer.